Formulations comprising antisense nucleotides to connexins
View Patent ↗A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.
1. A method of treating a human subject having a wound, which comprises administering to the wound a connexin 43 anti-sense polynucleotide, whereby connexin 43 protein expression is downregulated.
2. A method of reducing cell death resulting from a neuronal insult to a human subject, which comprises administering to the site of the neuronal insult a connexin 43 anti-sense polynucleotide, whereby connexin 43 expression is downregulated.
3. A method according to claim 2 wherein the neuronal insult is to the brain, spinal cord or optic nerve.
4. A method according to claim 2 in which said anti-sense polynucleotide is administered in a sufficient amount to downregulate connexin 43 expression for at least 24 hours post-administration.
5. A method of promoting wound healing in a human which comprises the step of administering to the wound an amount of a connexin 43 anti-sense polynucleotide effective to downregulate connexin 43 expression.
6. A method according to claim 1 or 5 in which the wound is the result of trauma.
7. A method according to claim 6 in which trauma is a burn.
8. A method according to claim 1 or 5 in which the wound is the result of a surgery.
9. A method of treating a human subject to reduce inflammation associated with a wound or associated with a tissue subjected to a physical trauma which comprises the step of administering to the wound or tissue an amount of a connexin 43 anti-sense polynucleotide effective to downregulate a connexin 43 expression.
10. A method according to claim 9 in which the tissue subjected to physical trauma is selected from the group consisting of brain, spinal cord and optic nerve.
11. A method of decreasing scar formation following a wound to a human subject which comprises administering to the wound an amount of a connexin 43 anti-sense polynucleotide effective to downregulate a connexin 43 expression.
12. A method according to claim 1 , wherein said anti-sense polynucleotide is an oligodeoxynucleotide.
13. A method according to any of claims 1 , 2 , 5 , 9 , or 11 wherein said connexin protein comprises the amino acid sequence coded for by SEQ ID NO. 12.
14. A method according to any of claims 1 , 2 , 5 , 9 , or 11 wherein said anti-sense polynucleotide is present in a composition comprising a pharmaceutically acceptable carrier or vehicle.
15. A method according to claim 14 , wherein said composition is suitable for topical administration.
16. A method according to claim 14 , wherein said composition is formulated to provide sustained release of the antisense polynucleotide.
17. A method according to claim 14 , wherein said composition is formulated to provide sustained release of the antisense polynucleotide over at least 24 hours.
18. A method according to claim 13 , wherein the anti-sense polynucleotide is present in a composition comprising a pharmaceutically acceptable carrier or vehicle formulated for topical administration.
19. A method according to claim 13 , wherein the anti-sense polynucleotide is in the form of an impregnated dressing.
20. A method according to claim 14 , wherein the pharmaceutically acceptable carrier or vehicle is, or includes, a gel.
21. A method according to claim 20 in which the gel is a nonionic polyoxyethylene-polyoxypropylene copolymer gel.
22. A method according to claim 14 , wherein the composition further includes a surfactant.
23. A method of decreasing cell death in a tissue of a mammal comprising contacting the cells with an effective amount of a connexin 43 antisense polynucleotide.
24. The method of claim 23 , wherein said connexin 43 antisense polynucleotide is an oligodeoxynucleotide.
25. The method of claim 24 , wherein said oligodeoxynucleotide is an unmodified phosphodiester oligomer.
26. The method of any of claims 1 , 2 , 5 , 9 , 11 or 23 , wherein said connexin 43 antisense polynucleotide binds to at least a portion of a connexin 43 mRNA.
27. The method of claim 26 , wherein said connexin 43 antisense polynucleotide is exactly complementary to at least a portion of said connexin 43 mRNA.
28. The method of claim 26 , wherein said connexin 43 antisense polynucleotide is not exactly complementary to at least a portion of a connexin 43 mRNA.
29. The method of any of claims 1 , 2 , 5 , 9 , 11 or 23 , wherein said connexin 43 antisense polynucleotide is about 12 to about 40 nucleotides in length.
30. The method of any of claims 1 , 2 , 5 , 9 , 11 or 23 , wherein said connexin 43 antisense polynucleotide is about 30 nucleotides in length.
31. The method of any of claims 1 , 2 , 5 , 9 , 11 or 23 , wherein said connexin 43 antisense polynucleotide comprises SEQ ID NO: 1.
32. The method of any of claims 1 , 2 , 5 , 9 , 11 or 23 , wherein said connexin 43 antisense polynucleotide comprises SEQ ID NO: 2.
33. The method of any of claims 1 , 2 , 5 , 9 , 11 or 23 , wherein said connexin 43 antisense polynucleotide comprises SEQ ID NO: 3.
34. The method of claim 23 , wherein said connexin 43 is a human connexin 43.
35. The method of claim 23 , wherein said mammal is a human.
36. The method of claim 23 , wherein said tissue is skin.
37. The method of claim 9 or 23 , wherein said tissue is neural tissue.
38. The method of claim 9 or 23 , wherein said tissue is brain.
39. The method of claim 9 or 23 , wherein said tissue is spinal cord.
40. The method of claim 9 or 23 , wherein said tissue is connective tissue.
41. The method of any of claims 23 – 25 , 34 , 35 or 36 , wherein said connexin 43 antisense polynucleotide is administered to a wound.
42. The method of claim 41 , wherein said wound is a surgical wound.
43. The method of claim 41 , wherein said wound is a burn.
44. The method of any of claims 23 – 25 , 34 , 35 or 36 , wherein said connexin 43 antisense polynucleotide is administered to a site of inflammation.
45. The method of any of claims 23 – 25 , 34 , 35 or 36 , wherein said connexin 43 antisense polynucleotide is disposed in a topical formulation.
46. The method of claim 45 , wherein said topical formulation comprises a gel.
47. The method of claim 46 , wherein said gel is a pluronic gel.
48. The method of any of claims 23 – 25 , 34 , 35 or 36 , wherein said connexin 43 antisense polynucleotide is administered by syringe.
49. The method of any of claims 23 – 25 , 27 , 28 or 34 – 36 , wherein said connexin 43 antisense polynucleotide is administered as a gel.
50. The method of any of claim 26 , wherein said connexin 43 antisense polynucleotide is administered as a gel.
51. The method of any of claim 29 , wherein said connexin 43 antisense polynucleotide is administered as a gel.
52. The method of any of claim 30 , wherein said connexin 43 antisense polynucleotide is administered as a gel.
53. The method of any of claim 31 , wherein said connexin 43 antisense polynucleotide is administered as a gel.
54. The method of any of claim 32 , wherein said connexin 43 antisense polynucleotide is administered as a gel.
55. The method of any of claim 33 , wherein said connexin 43 antisense polynucleotide is administered as a gel.
56. The method of any of claim 37 , wherein said connexin 43 antisense polynucleotide is administered as a gel.
57. The method of any of claim 38 , wherein said connexin 43 antisense polynucleotide is administered as a gel.
58. The method of any of claim 39 , wherein said connexin 43 antisense polynucleotide is administered as a gel.
59. The method of any of claim 40 , wherein said connexin 43 antisense polynucleotide is administered as a gel.
60. The method of any of claims 23 – 25 , 27 , 28 or 34 – 36 , wherein said connexin 43 antisense polynucleotide is administered as a dressing.
61. The method of claim 26 , wherein said connexin 43 antisense polynucleotide is administered as a dressing.
62. The method of claim 29 , wherein said connexin 43 antisense polynucleotide is administered as a dressing.
63. The method of claim 30 , wherein said connexin 43 antisense polynucleotide is administered as a dressing.
64. The method of claim 31 , wherein said connexin 43 antisense polynucleotide is administered as a dressing.
65. The method of claim 32 , wherein said connexin 43 antisense polynucleotide is administered as a dressing.
66. The method of claim 33 , wherein said connexin 43 antisense polynucleotide is administered as a dressing.
67. The method of claim 37 , wherein said connexin 43 antisense polynucleotide is administered as a dressing.
68. The method of claim 38 , wherein said connexin 43 antisense polynucleotide is administered as a dressing.
69. The method of claim 39 , wherein said connexin 43 antisense polynucleotide is administered as a dressing.
70. The method of claim 40 , wherein said connexin 43 antisense polynucleotide is administered as a dressing.